Cardiovascular

• 
• 
• 
• 

Researchers at Vanderbilt have created a novel drug delivery system using two distinct T-cell populations that interact to promote engraftment and persistence in pre-clinical models, increasing the efficacy of T-cell therapies. Furthermore, "booster" treatments can be administered months after the first dose to produce an expansion of antigen specific T cells. These advantages result in longer-term therapeutic efficacy and could reduce the number of treatments required. This system also represents a viable self-renewing platform for the delivery of biologic drugs in patients who would otherwise require frequent administration.

Recent FDA approvals have spurred the demand for viral vector products,prompting the need for more efficient bioproduction methods. In this context,Vanderbilt researchers have engineered a new cell line with significantlyenhanced viral production capabilities compared to traditional cell lines. Thisinnovation is expected to lead to substantial cost savings in viral vectorproduction and improved viral products, two key advantages in the industry.

Transesophageal echocardiography (TEE) is a test that uses high-frequency sound waves to create images of the heart. It provides more detail that a standard echocardiogram. Vanderbilt researchers have created a software that creates an easy to follow, step-by-step procedure for a transesophageal echocardiography exam.

This research targets eNOS.